Cancer Policy Kennedy: “We’re going to end the war at FDA against alternative medicine” June 13, 2025Vol.51 No.23By Jacquelyn Cobb
Drugs & Targets FDA approves Ibtrozi oral treatment for advanced ROS1+ NSCLC June 13, 2025Vol.51 No.23
Cancer Policy FDA booth stood empty at 2025 ASCO annual meeting June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Cancer Policy Makary: Level of evidence is an artificial and dogmatic construct June 06, 2025Vol.51 No.22By Jacquelyn Cobb
Drugs & Targets FDA approves Nubeqa for metastatic castration-sensitive prostate cancer June 06, 2025Vol.51 No.22
Drugs & Targets FDA grants priority review for sevabertinib in HER2-mutant NSCLC May 30, 2025Vol.51 No.21
Drugs & Targets Alligator Bioscience announces European orphan drug designation for HLX22 in gastric cancer May 30, 2025Vol.51 No.21
